Table 2.

Stepped dose titrations and second, third, and fourth line agents used in HALT study A and B

StepsTreatmentControl
Study A
    1–4Combination ACEi/ARBCombination ACEi/Placebo
    Lisinopril 5 mg/Telmisartan 40 mg    Lisinopril 5 mg/Placebo 40 mg
    Lisinopril 10 mg/Telmisartan 40 mg    Lisinopril 10 mg/Placebo 40 mg
    Lisinopril 20 mg/Telmisartan 80 mg    Lisinopril 20 mg/Placebo 80 mg
    Lisinopril 40 mg/Telmisartan 80 mg    Lisinopril 40 mg/Placebo 80 mg
    5Hydroclorothiazide 12.5 mg qdHydroclorothiazide 12.5 mg qd
    6–8Metoprolol 50 mg BIDMetoprolol 50 mg BID
Metoprolol 100 mg BIDMetoprolol 100 mg BID
Metoprolol 200 mg BIDMetoprolol 200 mg BID
    ≥9Nondihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at discretion of investigatorNondihydropyridine calcium channel blockers (diltiazem), minoxidil, clonidine, hydralazine at discretion of investigator
Study B
    1–4Combination ACEi/ARBCombination ACEi/Placebo
    Lisinopril 5 mg/Telmisartan 40 mg    Lisinopril 5 mg/Placebo 40 mg
    Lisinopril 10 mg/Telmisartan 40 mg    Lisinopril 10 mg/Placebo 40 mg
    Lisinopril 20 mg/Telmisartan 80 mg    Lisinopril 20 mg/Telmisartan 80 mg
    Lisinopril 40 mg/Placebo 80 mg    Lisinopril 40 mg/Placebo 80 mg
    5 and 6Furosemide 20 mg BIDFurosemide 20 mg BID
Furosemide 40 mg BIDFurosemide 40 mg BID
    7–9Metoprolol 50 mg BIDMetoprolol 50 mg BID
Metoprolol 100 mg BIDMetoprolol 100 mg BID
Metoprolol 200 mg BIDMetoprolol 200 mg BID
    ≥10Nondihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at discretion of investigatorNondihydropyridine calcium channel blockers (diltiazem), minoxidil, clonidine, hydralazine at discretion of investigator